Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Summary: Breakthrough infections induce more potent and durable antibody responses compared to those in unvaccinated individuals, providing better protection against spike mutations in variants. Multiple exposures to SARS-CoV-2 antigen enhance the quality of antibody responses. Developing vaccines with broad sarbecovirus immunity is crucial for pandemic preparedness.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.
Article
Medicine, General & Internal
Emma K. Accorsi et al.
Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Letter
Medicine, General & Internal
Timothy A. Bates et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Letter
Virology
Perumal A. Desingu et al.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.
Article
Multidisciplinary Sciences
Raquel Viana et al.
Summary: The SARS-CoV-2 epidemic in southern Africa has experienced three distinct waves, driven by different variants. The recently identified Omicron variant has rapidly spread in South Africa and to numerous countries, raising global concern.
Article
Multidisciplinary Sciences
Rigel Suzuki et al.
Summary: The Omicron variant of SARS-CoV-2 has spread rapidly in several countries and has shown lower fusogenicity and attenuated pathogenicity compared to the Delta variant.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Biochemistry & Molecular Biology
Hung Fu Tseng et al.
Summary: A test-negative case-control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.
Letter
Medicine, General & Internal
Rolando Pajon et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Young-Jun Park et al.
Summary: Understanding broadly neutralizing sarbecovirus antibody responses is crucial for developing countermeasures against SARS-CoV-2 variants and future sarbecoviruses. The human monoclonal antibody S2K146 has been found to broadly neutralize ACE2-binding viruses and shows potential for clinical development. Conserved ACE2-binding residues could be leveraged for developing vaccines that elicit broad immunity.
Article
Cell Biology
David R. Martinez et al.
Summary: Severe acute respiratory syndrome coronaviruses (SARS-CoVs), including SARS-CoV-2 variants, can cause deadly infections. A human antibody called DH1047 has been shown to neutralize SARS-CoV and various coronaviruses, and protect against SARS-CoV-2 B.1.351 infection in mice. The study suggests that DH1047 could be a broadly protective antibody and a potential target for a universal sarbecovirus vaccine.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Medicine, General & Internal
Lorenzo Azzi et al.
Summary: BNT162b2 COVID-19 vaccine induces strong systemic immune response but poorly activates mucosal immunity.
Article
Biochemistry & Molecular Biology
Matthew Gagne et al.
Summary: This study shows that both mRNA-1273 and mRNA-Omicron generate comparable immunity and protection after booster doses, and are able to neutralize the Omicron variant.
Article
Microbiology
Simone I. Richardson et al.
Summary: The Omicron variant of SARS-CoV-2 can evade neutralizing antibodies generated by either vaccines or previous infection. However, it is unclear whether Omicron can trigger cross-reactive immune responses to other variants of concern (VOCs). A study found that unvaccinated individuals produced binding antibodies and functional antibodies at similar levels against Omicron and other VOCs, but the neutralizing activity against VOCs was significantly reduced compared to Omicron. On the other hand, vaccinated individuals who experienced breakthrough Omicron infection had enhanced cross-neutralization against VOCs, indicating a potential benefit of vaccination in protecting against circulating and emerging variants.
CELL HOST & MICROBE
(2022)
Letter
Medicine, General & Internal
Annika Roessler et al.
Summary: Although some antibodies generated in persons recovering from infection with the omicron variant show cross-reactivity, a group of unvaccinated individuals were found to have largely ineffective antibodies against other viral strains.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The SARS-CoV-2 Omicron variant evades antibody-mediated immunity and exhibits enhanced affinity for host cells due to accumulation of spike mutations and remodeling of interactions with the ACE2 receptor.
Article
Cell Biology
Ai-Ris Y. Collier et al.
Summary: Vaccinated individuals who tested positive for SARS-CoV-2 Delta variant showed robust antibody and T cell responses, indicating the potential increase in population immunity through vaccination and breakthrough infections.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Cell Biology
Stephanie N. Langel et al.
Summary: Vaccination through oral or intranasal routes can generate strong antibody responses, reduce viral load in the nose and lungs, and mitigate lung pathology caused by SARS-CoV-2. Mucosally vaccinated hamsters transmitted fewer viruses with less severity to naive hamsters, suggesting that mucosal immunization can reduce viral transmission. In a clinical trial, the same platform also induced mucosal cross-reactive antibody responses.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Cell Biology
Kathryn Westendorf et al.
Summary: A monoclonal antibody named LY-CoV1404 has been successfully isolated, which demonstrates highly potent neutralization against multiple variants of the SARS-CoV-2 virus. The binding site of LY-CoV1404 remains relatively conserved, allowing it to maintain its activity. This finding suggests that LY-CoV1404 has the potential to be an effective therapeutic agent against all known variants.
Article
Immunology
Jasmin Quandt et al.
Summary: The Omicron BA.1 breakthrough infection in BNT162b2-vaccinated individuals showed strong neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 variants. The memory B cells induced by the breakthrough infection targeted epitopes shared broadly among variants. The vaccination-imprinted memory B cell pool was capable of remodeling in response to heterologous SARS-CoV-2 spike glycoprotein exposure. However, variants that acquire alterations at conserved sites may have increased susceptibility to immune escape.
SCIENCE IMMUNOLOGY
(2022)
Article
Immunology
Joey Ming Er Lim et al.
Summary: Nasal-resident T cells specific for SARS-CoV-2 were detected in vaccinated individuals only after infection, highlighting the significance of nasal challenge in the formation of antiviral immunity at the site of infection.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
John E. Bowen et al.
Summary: The Omicron variant of concern, characterized by numerous spike mutations, exhibits enhanced binding to ACE2, reduced fusogenicity, and reduced neutralizing activity against plasma induced by infection or vaccines. However, booster doses based on the Wuhan-Hu-1 spike sequence significantly increase neutralizing antibody titers and breadth against multiple Omicron sublineages.
Article
Multidisciplinary Sciences
James Brett Case et al.
Summary: SARS-CoV-2 Omicron variant strains are less susceptible to therapeutic neutralizing antibodies. However, therapeutic antibodies S309 and AZD7442 can still reduce lung infection in a mouse model. Different antibodies have different mechanisms of protection against Omicron variants.
NATURE COMMUNICATIONS
(2022)
Article
Cell Biology
Victoria Stalls et al.
Summary: This study determines the cryoelectron microscopy structures of the Spike (S) protein of the Omicron BA.2 sub-lineage of the SARS-CoV-2 virus and compares it with the BA.1 sub-lineage. The BA.2 S protein exhibits tighter packing and improved thermostability due to mutations in the receptor-binding domain (RBD). The closed state of BA.2 S enhances RBD interactions and shows reduced accessibility of the fusion peptide to antibodies compared to BA.1.
Article
Immunology
Jinyi Tang et al.
Summary: SARS-CoV-2 mRNA vaccination induces strong immune responses in the circulation, but its effectiveness in the respiratory tract, especially against variants of concern like Omicron, is still uncertain. This study found lower neutralizing antibody responses in the respiratory tract of vaccinated individuals compared to COVID-19 convalescents, despite robust antibody responses in the blood. Vaccination also induced circulating B and T cell immunity, but these responses were absent in the respiratory tract. Mouse immunization experiments showed that systemic mRNA vaccination alone resulted in weak respiratory mucosal neutralizing antibody responses, but combining it with mucosal adenovirus-S immunization produced strong neutralizing antibody responses against both the ancestral virus and the Omicron variant. Overall, this study suggests that current COVID-19 vaccines are highly effective against severe disease, but provide limited protection against breakthrough infections, particularly by the Omicron sublineage.
SCIENCE IMMUNOLOGY
(2022)
Letter
Infectious Diseases
Chee-Wah Tan et al.
Article
Virology
Samuel S. M. Cheng et al.
Summary: This study found that subvariants BA.4 and BA.5 of the Omicron variant of SARS-CoV-2 are less susceptible to neutralization by antibodies elicited by the BNT162b2 and CoronaVac vaccines. However, three doses of BNT162b2 or a booster dose of BNT162b2 following two doses of CoronaVac can elicit detectable neutralizing antibody responses to BA.4 and BA.5. Vaccinated individuals with BA.2 infections also had higher levels of neutralizing antibodies against BA.4 and BA.5 compared to vaccine-naive individuals.
JOURNAL OF CLINICAL VIROLOGY
(2022)
Article
Cell Biology
Prabhu S. Arunachalam et al.
Summary: This study demonstrates the durable protection provided by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine against the Omicron BA.1 variant, as well as high neutralizing antibody titers against both the Omicron and Beta variants. The vaccine also induces persistent neutralization against a panel of sarbecoviruses and elicits persistent memory T and B cell responses.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Ana A. Weil et al.
Summary: New variants of the SARS-CoV-2 virus continue to emerge, with university testing programs providing vital surveillance data for public health responses. Despite vaccination and strict measures, the Omicron variant quickly became the dominant strain in a university population, leading to a surge in cases.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, Research & Experimental
Delphine Planas et al.
Summary: This study evaluated the duration of neutralizing antibody response after Pfizer BNT162b2 vaccination and found a significant reduction in neutralization efficacy against Omicron variants. Breakthrough infection led to a transient increase in neutralizing antibodies against Omicron subvariants, followed by a gradual decline after 5-6 months. Infection, but not vaccination, triggered a strong immunoglobulin A (IgA) response and detectable Omicron-neutralizing activity.
Article
Immunology
Alexandra Schafer et al.
Summary: The study shows that combined use of hu-mAbs is effective for prevention and therapy of SARS-CoV-2 infection, but in vivo protection is influenced by intact effector function.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Lorena Sanchez-Felipe et al.
Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.
Article
Multidisciplinary Sciences
Christian Gaebler et al.
Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.
Article
Multidisciplinary Sciences
C. Garrett Rappazzo et al.
Summary: The engineered antibody ADG-2 shows enhanced neutralization breadth and potency against a wide range of sarbecoviruses, providing complete protection in SARS and COVID-19 mouse models. Structural and biochemical studies reveal that ADG-2 targets a highly conserved epitope through a unique angle of approach.
Article
Biochemistry & Molecular Biology
Emma C. Thomson et al.
Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.
Article
Multidisciplinary Sciences
Elisabetta Cameroni et al.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Summary: The study found that neutralizing antibody responses against several variants of concern gradually declined after vaccination with the mRNA-1273 vaccine for the SARS-CoV-2 virus. However, boosting nonhuman primates with either homologous or heterologous mRNA-1273 vaccines after 6 months resulted in increased neutralizing antibody responses across all variants of concern, which lasted for at least 8 weeks after the boost. After being challenged with the SARS-CoV-2 Beta variant 9 weeks post-boost, viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, indicating the potential necessity for booster vaccinations to maintain immunity and protection.
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The transmission of SARS-CoV-2 leads to the emergence of variants, such as the B.1.617.2 (Delta) variant, which dampens the in vitro potency of vaccine-elicited serum neutralizing antibodies. Mutations in the B.1.617.1 (Kappa) and Delta spike glycoproteins alter key antigenic sites, affecting the recognition by monoclonal antibodies. The angiotensin-converting enzyme 2 binding affinities of Kappa and Delta are comparable to the Wuhan-Hu-1 isolate, while Delta+ exhibits significantly reduced affinity.
Article
Biochemistry & Molecular Biology
Matthew McCallum et al.
Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article
Immunology
Ji Eun Oh et al.
Summary: Research shows that intranasal immunization induces local IgA secretion in the bronchoalveolar space, providing effective protection against respiratory virus infections; single-cell RNA sequencing reveals a heterogeneous population of IgA-expressing cells within the respiratory mucosa, including tissue-resident memory B cells, plasmablasts, and plasma cells.
SCIENCE IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Leonidas Stamatatos et al.
Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Summary: Understanding the protective effects of vaccines against SARS-CoV-2 variants and other sarbecoviruses is crucial for guiding public health policies. This study demonstrates that a multivalent sarbecovirus RBD-NP vaccine can protect mice from SARS-CoV-2 challenge after a single immunization, suggesting a potential dose-sparing strategy. The research also shows that antibodies induced by the multivalent sarbecovirus RBD-NPs exhibit similar resilience to various RBD residue substitutions.
Article
Multidisciplinary Sciences
Florian A. Lempp et al.
Summary: The study reveals that C-type lectin receptors and other factors can serve as attachment receptors for SARS-CoV-2 infection, enhancing ACE2-mediated infection and modulating the neutralizing activity of antibodies.
Article
Multidisciplinary Sciences
M. Alejandra Tortorici et al.
Summary: The emergence of SARS-CoV-2 variants and recurrent spillovers of coronaviruses into the human population emphasize the need for broadly neutralizing antibodies to prevent future zoonotic infections. The human monoclonal antibody S2X259 has shown promising results in neutralizing various forms of SARS-CoV-2 and potentially zoonotic sarbecoviruses by inhibiting the binding of ACE2 to the receptor-binding domain. This antibody targets a key antigenic site and may guide the design of vaccines effective against all sarbecoviruses.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.
Article
Multidisciplinary Sciences
Tyler N. Starr et al.
Summary: An ideal therapeutic anti-SARS-CoV-2 antibody should have resistance to viral escape, activity against diverse sarbecoviruses, and provide high protection through viral neutralization and effector functions. Studies have found a trade-off between in vitro neutralization potency and breadth of sarbecovirus binding in SARS-CoV-2 antibodies targeting the RBD, but identified some antibodies with exceptional sarbecovirus breadth and resistance to SARS-CoV-2 escape.
Article
Medicine, General & Internal
Chee-Wah Tan et al.
Summary: Survivors of SARS-CoV-1 infection who received the BNT162b2 mRNA vaccine produced potent cross-clade pan-sarbecovirus neutralizing antibodies, capable of neutralizing various variants of concern and potential human-infecting coronaviruses, indicating the feasibility of a pan-sarbecovirus vaccine strategy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Multidisciplinary Sciences
Shane Crotty
Article
Multidisciplinary Sciences
David R. Martinez et al.
Summary: The emergence of SARS-CoV in 2003 and SARS-CoV-2 in 2019 has led to the development of universal vaccination strategies against the broader Sarbecovirus subgenus. Through the use of chimeric spike designs, high levels of broadly protective neutralizing antibodies have been induced against various high-risk Sarbecoviruses, showing potential for preventing SARS-like zoonotic coronavirus infections with pandemic potential.
Article
Multidisciplinary Sciences
Dora Pinto et al.
Summary: The study identified five monoclonal antibodies from COVID-19 convalescent individuals that cross-react with multiple betacoronavirus spike glycoproteins, with one antibody (S2P6) showing broad neutralization of viruses from three different subgenera. This antibody reduced viral burden in hamsters challenged with SARS-CoV-2 by inhibiting membrane fusion, providing a framework for the design of pan-betacoronavirus vaccines for broad protection.
Article
Cell Biology
Allison J. Greaney et al.
Summary: Vaccine-elicited antibodies have more focused neutralizing activity on the RBD of the SARS-CoV-2 spike protein, while infection-elicited antibodies have broader binding across epitopes; hence, single RBD mutations have less impact on neutralization by vaccine sera.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Microbiology
Jinhui Dong et al.
Summary: Structural analysis of two human monoclonal antibodies forming the antibody cocktail AZD7442, when bound to the RBD of SARS-CoV-2, demonstrates strong neutralization of variants of concern. Genetic and structural basis of neutralization has been defined, revealing crucial binding residues and positions of concern for virus escape. These germ line-encoded antibody features enable recognition of SARS-CoV-2 spike RBD and showcase the utility of cocktail AZD7442 in neutralizing emerging variant viruses.
NATURE MICROBIOLOGY
(2021)
Article
Multidisciplinary Sciences
Petra Mlcochova et al.
Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.
Article
Cell Biology
Ahmed O. Hassan et al.
Summary: The study demonstrates the immunogenicity and protective efficacy of an intranasally administered vaccine in non-human primates, showing that it induces neutralizing antibodies and T cell responses, effectively limiting or preventing infection of SARS-CoV-2 in the respiratory tract.
CELL REPORTS MEDICINE
(2021)
Article
Multidisciplinary Sciences
Alexander A. Cohen et al.
Summary: The study developed nanoparticles displaying the receptor binding domain (RBD) of SARS-CoV-2 and other animal coronaviruses, which induced cross-reactive antibody responses in mice. Immunization with mosaic RBD nanoparticles resulted in superior neutralization of heterologous viruses, providing a potential strategy for simultaneous protection against multiple coronaviruses.
Article
Infectious Diseases
Victor M. Corman et al.
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Article
Virology
Katharine H. D. Crawford et al.
Article
Multidisciplinary Sciences
Dora Pinto et al.
Article
Multidisciplinary Sciences
Jun Lan et al.
Article
Microbiology
James Brett Case et al.
CELL HOST & MICROBE
(2020)
Letter
Medicine, General & Internal
Denise J. McCulloch et al.
Article
Biochemistry & Molecular Biology
Luca Piccoli et al.
Article
Biotechnology & Applied Microbiology
Chee Wah Tan et al.
NATURE BIOTECHNOLOGY
(2020)
Article
Multidisciplinary Sciences
Suzanne J. F. Kaptein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Multidisciplinary Sciences
M. Alejandra Tortorici et al.
Article
Cell Biology
Crystal Sao-Fong Cheung et al.
Article
Biochemical Research Methods
Ali Punjani et al.
Article
Multidisciplinary Sciences
Robbert Boudewijns et al.
NATURE COMMUNICATIONS
(2020)
Article
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
Article
Biochemical Research Methods
Dimitry Tegunov et al.
Article
Biochemistry & Molecular Biology
Brandon Frenz et al.
Article
Chemistry, Multidisciplinary
Jasenko Zivanov et al.
Article
Biochemical Research Methods
Tristan Ian Croll
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY
(2018)
Article
Biology
Jasenko Zivanov et al.
Article
Chemistry, Multidisciplinary
Daniel R. Roe et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY
(2018)
Article
Biochemical Research Methods
Ali Punjani et al.
Article
Multidisciplinary Sciences
Katelyn M. Gostic et al.
Article
Biology
Ray Yu-Ruei Wang et al.
Article
Chemistry, Physical
James A. Maier et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION
(2015)
Article
Microscopy
Shaoxia Chen et al.
Article
Immunology
Jens Wrammert et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2011)
Article
Multidisciplinary Sciences
Davide Corti et al.
Article
Biochemical Research Methods
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
(2010)
Article
Immunology
Debora Pinna et al.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2009)
Review
Chemistry, Physical
In Suk Joung et al.
JOURNAL OF PHYSICAL CHEMISTRY B
(2008)
Review
Chemistry, Multidisciplinary
Karl N. Kirschner et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY
(2008)
Article
Biochemistry & Molecular Biology
C Suloway et al.
JOURNAL OF STRUCTURAL BIOLOGY
(2005)
Article
Chemistry, Multidisciplinary
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY
(2004)
Article
Biochemistry & Molecular Biology
PB Rosenthal et al.
JOURNAL OF MOLECULAR BIOLOGY
(2003)
